Shield Therapeutics (LON:STX) Trading Down 8.2% – Here’s Why

Shares of Shield Therapeutics plc (LON:STX) were down 8.2% during trading on Wednesday . The company traded as low as GBX 2.30 ($0.03) and last traded at GBX 2.47 ($0.03). Approximately 340,861 shares changed hands during trading, a decline of 86% from the average daily volume of 2,433,621 shares. The stock had previously closed at GBX 2.69 ($0.04).

Shield Therapeutics Stock Down 4.4%

The company has a quick ratio of 2.16, a current ratio of 1.05 and a debt-to-equity ratio of 3,691.50. The company has a market capitalization of £23.59 million, a PE ratio of -0.62 and a beta of 1.42. The business’s 50 day simple moving average is GBX 2.73 and its 200 day simple moving average is GBX 2.86.

Shield Therapeutics (LON:STX) last posted its quarterly earnings results on Thursday, April 24th. The company reported GBX (3) (($0.04)) earnings per share (EPS) for the quarter. Shield Therapeutics had a negative return on equity of 470.50% and a negative net margin of 173.43%. As a group, analysts forecast that Shield Therapeutics plc will post 0.0707619 EPS for the current year.

Insider Activity at Shield Therapeutics

In other Shield Therapeutics news, insider Anders Lundstrom purchased 575,000 shares of the firm’s stock in a transaction on Thursday, February 13th. The shares were purchased at an average price of GBX 4 ($0.05) per share, for a total transaction of £23,000 ($30,609.53). Insiders own 62.16% of the company’s stock.

Shield Therapeutics Company Profile

Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S.